InnoCare Pharma News

Announcement on voluntary disclosure of ICP-488 phase II clinical trial results by Nuochengjianhua Pharmaceutical Co., Ltd.

Oct 10 00:00

Nuochengjianhua: Announcement of Nuochengjianhua Pharmaceutical Co., Ltd. on the resignation of non-executive directors and independent non-executive directors and the change of members of the Board of Directors Special Committee

Sep 26 00:00

Hong Kong Stock Announcement: List of Directors and Their Roles and Functions

Sep 26 00:00

Announcement of Nuochengjianhua Pharmaceutical Co., Ltd. on the resignation of non-executive directors and independent non-executive directors and the change of members of the special committee of the board

Sep 26 00:00

Announcement of Nuocheng Jianhua Pharmaceutical Co., Ltd. on changing the sponsor representative for continuous supervision

Sep 21 00:00

Nuochengjianhua Pharmaceutical Co., Ltd. voluntarily disclosed the progress of clinical trials of obutinib

Sep 9 00:00

InnoCare Pharma: Board of directors meeting date.

Aug 8 00:00

InnoCare Pharma: Monthly securities change report.

Aug 6 00:00

Innocare Pharmaceutical voluntarily discloses the announcement of the first dosing of ICP-332 trial subjects in the United States.

Jul 25 00:00

InnoCare Pharma: Disclosure of the financial report on the following day.

Jul 20 00:00

Innocare Pharmaceutical Co., Ltd.'s announcement regarding the "Improve Efficiency and Return to Increase Quality" action plan for 2024.

Jul 18 00:00

InnoCare Pharma: Monthly securities change report.

Jul 5 00:00

Announcement of the resolutions of the 2024 Shareholders' Annual Meeting of Innocare Pharmaceutical Co., Ltd.

Jun 28 00:00

Innocare Pharmaceutical Co., Ltd. Announcement on using idle self-owned funds for cash management.

Jun 26 00:00

Announcement of innocare pharmaceutical co., LTD. on the cancellation of some unallocated restricted stocks.

Jun 26 00:00

Innocare Pharmaceuticals voluntarily disclosed an announcement regarding the acceptance by the National Medical Products Administration of the biological product license for tafasitamab and lenalidomide in the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Jun 21 00:00

InnoCare Pharma: Monthly securities change report.

Jun 5 00:00

InnoCare Pharma: Monthly statement of changes in securities

May 7 00:00

InnoCare Pharma: Date of Board Meeting

Apr 30 00:00

Meeting materials of the 2024 Annual General Meeting of Shareholders of Nuochengjianhua Pharmaceutical Co., Ltd.

Apr 27 00:00